Indian Healthcare Sector: A Steady Performance Expected in Q3 FY26
Motilal Oswal has projected a steady performance for the Indian healthcare sector in Q3 FY26, supported by improving domestic formulations momentum. However, increased competition in select products for the US market and a slower pace of potential launches should keep Ebitda growth trend in check.
Domestic Formulations to Drive Growth
Domestic formulations are expected to grow 8.7% YoY to Rs 25,600 crore, led by chronic therapies such as cardiac and anti-diabetic, while acute therapies remain subdued. This growth is expected to be driven by the increasing demand for healthcare services in India, particularly in the chronic disease segment.
According to Motilal Oswal, the Indian healthcare sector is expected to benefit from the government’s initiatives to improve healthcare infrastructure and increase access to healthcare services. The healthcare sector in India is also expected to benefit from the growing demand for generic medicines and the increasing presence of Indian pharmaceutical companies in the global market.
Laurus Labs, Biocon, and Rubicon: Top Picks
Motilal Oswal has identified Laurus Labs, Biocon, and Rubicon as its top picks in the Indian healthcare sector. These companies are expected to benefit from the growing demand for healthcare services in India and the increasing presence of Indian pharmaceutical companies in the global market.
Laurus Labs is a leading manufacturer of active pharmaceutical ingredients (APIs) and intermediates. The company has a strong presence in the global market and is expected to benefit from the growing demand for generic medicines.
Biocon is a leading biopharmaceutical company in India, with a strong presence in the global market. The company has a diversified portfolio of products, including APIs, biosimilars, and branded formulations.
Rubicon is a leading manufacturer of APIs and intermediates, with a strong presence in the global market. The company has a diversified portfolio of products and is expected to benefit from the growing demand for generic medicines.
Investment Strategy
Investors looking to invest in the Indian healthcare sector can consider the top picks identified by Motilal Oswal, including Laurus Labs, Biocon, and Rubicon. However, it is essential to do your own research and consider your investment goals and risk tolerance before making any investment decisions.
Investors can also consider investing in healthcare sector index funds or exchange-traded funds (ETFs), which provide a diversified portfolio of stocks in the healthcare sector.
Conclusion
In conclusion, the Indian healthcare sector is expected to perform steadily in Q3 FY26, driven by improving domestic formulations momentum. Laurus Labs, Biocon, and Rubicon are the top picks in the sector, and investors can consider investing in these companies or healthcare sector mutual funds to benefit from the growth in the sector.